Cargando…
Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients
BACKGROUND: Psoriasis is a common chronic inflammatory skin disease associated with overproduction of interleukin-17A (IL-17A). IL-17A monoclonal antibodies (mAbs) have shown clinical efficacy in psoriasis patients. Although a series of different overlapping mechanisms have been found to establish a...
Autores principales: | Cao, Han, Su, Shengmin, Yang, Qi, Le, Yunchen, Chen, Lihong, Hu, Mengyan, Guo, Xiaoyu, Zheng, Jie, Li, Xia, Yu, Yunqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890626/ https://www.ncbi.nlm.nih.gov/pubmed/33602246 http://dx.doi.org/10.1186/s12944-021-01441-9 |
Ejemplares similares
-
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
por: von Stebut, Esther, et al.
Publicado: (2020) -
Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
por: Pangilinan, Mary Catherine G., et al.
Publicado: (2020) -
Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014) -
Interleukin-17A and Keratinocytes in Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2020) -
Aberrations in Lipid Expression and Metabolism in Psoriasis
por: Nowowiejska, Julia, et al.
Publicado: (2021)